SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parmax Pharma - Quaterly Results

14 Feb 2025 Evaluate
The Total revenue for the quarter ended December 2024 of  Rs. 62.84 millions grew by 373.55% from Rs. 13.27 millions.The Net Loss for the quarter ended December 2024 is Rs. -3.94 millions as compared to Net Loss of Rs. -17.53 millions of corresponding quarter ended December 2023 Operating profit Margin for the quarter ended December 2024 improved to 1.21% as compared to -11.43% of corresponding quarter ended December 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 62.84 13.27 373.55 233.77 67.95 244.03 110.53 154.24 -28.34
Other Income 0.13 0.11 18.18 1.38 0.34 305.88 0.48 0.40 20.00
PBIDT 1.21 -11.43 -110.59 9.58 -25.36 -137.78 -33.23 22.93 -244.92
Interest 1.06 1.56 -32.05 3.48 4.59 -24.18 6.22 3.69 68.56
PBDT 0.15 -12.99 -101.15 6.10 -29.95 -120.37 -39.45 19.24 -305.04
Depreciation 4.09 4.54 -9.91 12.08 13.05 -7.43 17.12 18.79 -8.89
PBT -3.94 -17.53 -77.52 -5.98 -43.00 -86.09 -56.57 0.45 -12671.11
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.95 1.50 -36.67
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.95 -0.35 -371.43
PAT -3.94 -17.53 -77.52 -5.98 -43.00 -86.09 -57.52 -1.05 5378.10
Equity 37.41 37.41 0.00 37.41 37.41 0.00 37.41 37.41 0.00
PBIDTM(%) 1.93 -86.13 -102.24 4.10 -37.32 -110.98 -30.06 14.87 -302.23

Parmax Pharma Share Price

32.99 1.29 (4.07%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×